DDInter1676 DDInter1847
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or
Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of its class. Trastuzumab deruxtecan was developed by Daiichi Sankyo in collaboration with AstraZeneca and was first approved by the FDA in 2019.
Trastuzumab deruxtecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sipuleucel-T
Trastuzumab deruxtecan {u} may lead to a major life threatening interaction when taken with {v} Samarium (153Sm) lexidronam
Trastuzumab deruxtecan {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Trastuzumab deruxtecan may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Trastuzumab deruxtecan may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Trastuzumab deruxtecan may lead to a major life threatening interaction when taken with Upadacitinib